Fluvoxamine Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 50 mg, 100 mg
Reference Brands: Luvox(US); Fevarin(EU)
Category:
Antipsychotropic Drugs
Fluvoxamine tablets are selective serotonin reuptake inhibitors (SSRIs) that work by increasing serotonin levels in the brain to help improve mood and reduce anxiety. They are primarily used to treat obsessive-compulsive disorder (OCD) and depression, alleviating symptoms such as persistent thoughts, compulsive behaviors, and emotional imbalance in affected patients.
Fluvoxamine Tablets is available in Tablets
and strengths such as 25 mg, 50 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fluvoxamine Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fluvoxamine Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
In the USA, fluvoxamine extended-release capsules are FDA-approved for the treatment of obsessive-compulsive disorder (OCD) and social anxiety disorder (SAD) in adults. As an SSRI, the product carries a Boxed Warning about increased risks of suicidal ideation in young adults. Regulatory requirements include GMP-compliant manufacturing, bioequivalence studies for generics, and continuous post-marketing safety monitoring through FDA’s FAERS database. Labeling must include specific safety and usage instructions aligned with approved indications.
In the EU, fluvoxamine is generally available in immediate-release form, with extended-release capsules not widely marketed. Any future EU submissions must comply with EMA or national authority requirements, including Risk Management Plans (RMPs), clinical safety data, and pharmacovigilance systems. For dossier-ready supply and global distribution, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing